Radiofrequency Ablation Devices Global Market Report 2024

The radiofrequency ablation devices market size has grown rapidly in recent years. It will grow from $4.27 billion in 2023 to $4.84 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The increase observed in the historical period can be attributed to clinical acceptance, a rise in chronic diseases, increased patient demand, regulatory approvals, and advancements in training and education.

The radiofrequency ablation devices market size is expected to see rapid growth in the next few years. It will grow to $7.6 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be attributed to the expanding geriatric population, advancements in regenerative medicine, the adoption of value-based healthcare, integration of telemedicine, and a shift towards minimally invasive procedures. Noteworthy trends expected during the forecast period include the development of portable ablation devices, the exploration of combination therapies, advancements in cancer ablation techniques, incorporation of enhanced safety features, and the integration of remote and robotic assistance.

The radiofrequency ablation devices market is anticipated to experience growth, propelled by the increasing prevalence of chronic diseases. These diseases, lasting a year or more and requiring ongoing medical attention, significantly impact individuals' daily lives. Radiofrequency ablation devices are instrumental in managing chronic and arthritic joint pain, as well as reducing the size of tumors or growths within the body. The National Library of Medicine projected a substantial 99.5% increase in individuals aged 50 and above with at least one chronic illness by 2050, reaching 142.66 million. This surge in chronic diseases is a key driver behind the expansion of the radiofrequency ablation devices market.

The factor contributing to the growth of the radiofrequency ablation devices market is the rising geriatric population. Defined as individuals aged 65 and older, the geriatric segment benefits from radiofrequency ablation devices, providing minimally invasive treatment options for age-related conditions such as pain management and cardiac arrhythmias. The World Health Organization estimates that by 2030, one in six individuals globally will be 60 or older, reaching a total of 2.1 billion elderly people by 2050. The increasing geriatric population is a significant factor propelling the growth of the radiofrequency ablation devices market.

A notable trend in the radiofrequency ablation devices market is the emphasis on technological advancement by major companies. These companies are actively innovating new technical solutions to maintain their market positions. For instance, Compal Electronics introduced AblatePal, a new radiofrequency ablation system designed for percutaneous and intraoperative coagulation and ablation of soft tissue. This system utilizes heat energy generated by electrical resistance to cauterize tumors and prevent damage to normal tissue through advanced cooling technology. Such technological innovations contribute to positive outcomes, reducing wound size and hospitalization duration.

Major companies in the radiofrequency ablation devices market are strategically introducing advanced medical devices to gain a competitive edge. The ELIOSTAR Balloon Ablation Catheter, launched by Biosense Webster Inc., is one such device designed for cardiac ablation procedures, offering innovative technology to treat arrhythmias with enhanced precision. The catheter, featuring unique one-shot balloon technology, enables pulmonary vein isolation in just 12 seconds, providing customized energy delivery and integrated 3D mapping solutions. This advancement aims to improve the efficiency and effectiveness of cardiac ablations, potentially reducing procedure time and increasing patient accessibility.

In August 2022, Medtronic PLC bolstered its position in the radiofrequency ablation devices market through the acquisition of Affera Inc., a medical technology company specializing in radiofrequency ablation devices. This strategic move allows Medtronic to expand its heart mapping and navigation platform, incorporating a fully integrated diagnostic, focal pulsed field, and radiofrequency ablation solution into its cardiac ablation portfolio. Affera Inc.'s expertise in producing radiofrequency ablation devices aligns with Medtronic's commitment to advancing cardiac care through innovative medical technologies.

Major companies operating in the radiofrequency ablation devices market report are Johnson And Johnson Co, Abbott Laboratories, Medtronic PLC, Siemens Healthineers, Becton, Dickinson and Company, Koninklijke Philips NV, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Smith And Nephew PLC, Ethicon Inc., Hologic Inc., Arthrex Inc., Halyard Health Inc., BIOTRONIK SE and Co KG, Merit Medical Systems Inc., Conmed Corporation, Avanos Medical Inc., ArtiCure Inc., AngioDynamics Inc., Biosense Webster Inc., Baylis Medical Company Inc., Sutter Medizintechnik GmbH, OSYPKA AG, Inomed Medizintechnik GmbH, St. Jude Medical Inc., Epimed International Inc.


North America was the largest region in the radiofrequency ablation devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiofrequency ablation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiofrequency ablation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of radiofrequency ablation devices include disposable equipment, reusable equipment, and capital equipment. Disposable equipment denotes medical devices designed for a single use or short duration. These are utilized in various applications, including oncology, cardiology and cardiac rhythm management, gynecology, pain management, among others, and are deployed by different end-users, such as hospitals, ambulatory surgical centers, and others.

The radiofrequency ablation devices market research report is one of a series of new reports that provides radiofrequency ablation devices market statistics, including radiofrequency ablation devices industry global market size, regional shares, competitors with a radiofrequency ablation devices market share, detailed radiofrequency ablation devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiofrequency ablation devices industry. This radiofrequency ablation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiofrequency ablation devices market consists of sales of catheters, thermopads, and hard tissue introducers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.